AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05616962 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Diosmiplex
Description: diosmin glycoside in combination with alkaline granules known as alka4-complex
Study NCT02247427 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy Device
Description: Cardiac Resynchronization Therapy Device pacing activity, on or off
Study NCT02970500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate HCl 10Mg SR
Description: Methylphenidate HCl 10Mg SR (Phase 1) and Methylphenidate HCl 20Mg SR (Phase 2)
Study NCT02970500 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: Placebo
Study NCT00931372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide (AVE0010)
Description: Solution for subcutaneous injection 100 µg/mL
Study NCT00931372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous injection
Study NCT03683069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone vs Amlodipine
Description: We posit that decreases in striatin activity/levels increases aldosterone secretion resulting in hypertension and salt sensitive blood pressure. Thus, our mechanistic clinical study will assess whether hypertensive striatin risk allele carriers will show significantly greater reductions in blood pressure with a specific aldosterone mediated treatment approach (mineralocorticoid receptor blockade) than with a non-specific approach (amlodipine). To test this hypothesis, we will perform a randomized, double-blind, active controlled study in hypertensive carriers of the striatin risk allele using a novel two-limb, proof-of-principle study. Our primary outcome will be a liberal salt diet systolic blood pressure with a secondary outcome of salt sensitive blood pressure. Therefore, this mechanistic trial will provide support for using a genetic marker that identifies individuals who are uniquely responsive to mineralocorticoid receptor blockade--personalized, precision medicine.
Study NCT03321916 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: 577-nm PASCAL laser
Description: The Topcon/Endpoint Management System™ is a cleared medical device commonly used in the treatment of ocular disorders.
Study NCT03321916 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 577-nm PASCAL laser
Description: The Topcon/Endpoint Management System™ is a cleared medical device commonly used in the treatment of ocular disorders.
Study NCT04429516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Sulfate
Description: over-encapsulated Morphine Sulfate prolonged release 5mg tablet, twice daily for 14 days. Patients will then crossover after a 7 day wash out period.
Study NCT04429516 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: capsule containing Microcrystalline Cellulose Ph. Eur, 5 mg twice daily
Study NCT03889743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone treatment during 3 days
Description: Dexamethasone 1,0 mg oral tablets. The exact daily dose of dexamethasone will be 0.3 mg/kg (maximum 6.0 mg). The recommended administration of all tablets is to crush the tablets to a smooth powder and then mix with jelly or yogurt. The dissolved dexamethasone is given by mouth and it is recommended to give it in relation to a meal/breastfeeding. If a child vomits within 30 min, the same dose will be given one more time after a break.
Study NCT03889743 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo treatment during 3 days
Description: 1,0 mg oral tablets. The exact daily dose of lactose (instead of dexamethasone) will be 0.3 mg/kg (maximum 6.0 mg). The recommended administration of all tablets is to crush the tablets to a smooth powder and then mix with jelly or yogurt. The dissolved dexamethasone is given by mouth and it is recommended to give it in relation to a meal/breastfeeding. If a child vomits within 30 min, the same dose will be given one more time after a break.
Study NCT06402734 — intervention group
Intervention type: BEHAVIORAL
Intervention: Adherence to Gluten Free Diet
Description: Participants with a diagnosed celiac disease were following a gluten-free diet. Study observed the adherence to the gluten-free diet for 6 weeks.
Study NCT01704170 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kona Externally Focused Ultrasound Therapy
Study NCT00302796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bioclavid
Description: 500 + 125 mg times 3 or 6
Study NCT00302796 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01009931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12-O-tetradecanoylphorbol-13-acetate
Description: The initial dose of TPA will be 1 mg/week x 3 weeks (Day 1, 8, 15). Up to 6 cycles.
Study NCT01009931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 10 mg PO qid will start 24h prior to TPA and continue for 24h after TPA x 3 weeks. Up to 6 cycles.
Study NCT01009931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Choline magnesium trisalicylate
Description: Choline magnesium trisalicylate 1500 mg PO TID will begin 24h prior to TPA and continue for 24h post TPA x 3 weeks.~Up to 6 cycles.
Study NCT02110641 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Loss Counseling
Description: The intervention will be based on the Diabetes Prevention Program weight loss program, which uses a combination of reduced caloric intake, increased physical activity, and behavior therapy. The content of the weight loss program will be similar for the in-person and telephone interventions, but the approach will vary (i.e., in-person vs. telephone counseling). The weight loss intervention will be conducted by a Registered Dietitian, who has training in exercise physiology and behavior modification.
Study NCT04137042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Intraoperative fluid therapy is administrated by using 0.9% saline
Study NCT04137042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balanced crystalloid
Description: Intraoperative fluid therapy is administrated by using balanced crystalloid
Study NCT02527668 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcifediol
Description: One capsule orally of Calcifediol (20 µg) per day with a meal for a duration of 6 months
Study NCT02527668 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: One capsule orally of Cholecalciferol (3200 IU) per day with a meal for a duration of 6 months
Study NCT02527668 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule orally of a Placebo capsule per day with a meal for a duration of 6 months
Study NCT01219348 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IDO peptide vaccination
Description: Vaccination every second week
Study NCT00479245 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Set of questionnaires (respondent)
Description: To determine the measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule)
Study NCT04546581 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)
Description: Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG) is derived from the plasma of individuals who recover and develop neutralizing antibodies. Participants will receive a single infusion.
Study NCT04546581 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a single infusion of the placebo (saline).
Study NCT04546581 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remdesivir
Description: Remdesivir will be given to participants in both groups as standard of care (SOC).
Study NCT04546581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Remdesivir will be given to participants in both groups as standard of care (SOC).
Study NCT02212756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1029M 1200mg and Metformin 1000mg
Description: Metformin 500mg 1 Tablet and DW1029M 300mg 2 Tablets b.i.d. for 7days
Study NCT02212756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin 1000mg
Description: Metformin 500mg b.i.d. for 7 days
Study NCT02638584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole
Description: Rabeprazole 20mg 1tablets once a day(1 times / day), before breakfast
Study NCT00719485 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational program
Description: Informing patients about their condition, treatment options, prioritization on the wait list, and post-operative care
Study NCT04366843 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chair massage
Description: Chair massage was performed useing only traditional methods of Swedish massage were used, consisting of stroking (smooth, continuous movements to relax and calm the sympathetic nervous system), kneading (consisting of wringing, squeezing muscles, compressing pressure points for the relaxation of soft tissues, i.e. muscles, tendons, fascia), stretching combined with swaying and passive movements of the upper limbs (to mobilize the joints of the upper limbs) and final stroking combined with slapping and shaking percussion, vibration.
Study NCT04366843 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the exercise program
Description: The original set of exercises was developed based on the knowledge and clinical experience of the authors of the study and based on EBP (Evidence Based Practice). The program consisted of 14 strengthening and stretching exercises involving the muscles of the trunk and limbs whose main goal was to mobilize the joints and strengthen the weakened muscles and relax overloaded muscle groups.
Study NCT02035202 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT2go
Description: CBT administered using mobile intervention.
Study NCT01702337 — intervention group
Intervention type: OTHER
Intervention: Prevalence-based model
Description: Static prevalence-based model to estimate vaccine effect over a one-year period at a steady state (when all women are fully vaccinated).
Study NCT01928719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reduced Nicotine Content Cigarettes
Description: Cigarettes contain 11.6, 7.4, 3.3, 1.4, 0.7, and 0.2 mg nicotine per cigarette
Study NCT01928719 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Same Nicotine Content Cigarettes
Description: about 11.6 mg nicotine per cigarette
Study NCT02648581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous Ustekinumab
Description: Injections of ustekinumab at 90 mg at week 0, week 4 and week 16. Patients in treatment failure at week 24 will terminate the study. Responder patients at week 24 will receive additional 2 injections of ustekinumab at week 28 and week 40 with a final evaluation at week 52.
Study NCT02043496 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrative Cognitive-Affective Therapy
Description: Integrative Cognitive-Affective Therapy is a psychotherapy treatment for binge eating that focuses on changing behaviors, feelings, thoughts, and relationships
Study NCT02043496 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-Guided Self Help
Description: CBT-Guided Self Help focuses on changing behavior patterns through the use of reading and homework assignments along with sessions with a therapist.
Study NCT02744534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FACBC PET-CT Scan
Description: One hour prior to scanning, participants will drink one glass (450 ml) of oral contrast to allow for better pictures of abdomen and pelvic organs. The participants will have their temperature taken before and after the injection of the FACBC. Blood pressure and pulse will be taken every 15 minutes during the PET scan.~Participants will lie on a scanning bed and the bed will move slowly through the PET/CT scanner. This portion usually takes about one minute. Following this the FACBC will by administered by an intravenous (IV) catheter and the PET scan portion of the exam will begin. The table moves slowly through the scanner and many sets of PET-CT images are produced. When the imaging is complete, the scanner will send the results to a computer. The computer then generates a number of images that will be reviewed by a specially trained radiologist.
Study NCT02744534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FACBC PET-CT Scan
Description: One hour prior to scanning, participants will drink one glass (450 ml) of oral contrast to allow for better pictures of abdomen and pelvic organs. The participants will have their temperature taken before and after the injection of the FACBC. Blood pressure and pulse will be taken every 15 minutes during the PET scan.~Participants will lie on a scanning bed and the bed will move slowly through the PET/CT scanner. This portion usually takes about one minute. Following this the FACBC will by administered by an intravenous (IV) catheter and the PET scan portion of the exam will begin. The table moves slowly through the scanner and many sets of PET-CT images are produced. When the imaging is complete, the scanner will send the results to a computer. The computer then generates a number of images that will be reviewed by a specially trained radiologist.
Study NCT02744534 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Three-dimensional ultrasound-guided biopsy
Description: A lubricated rectal probe will be inserted and a local anesthetic to numb the prostate will be administered. The ultrasound probe allows visualization of the prostate in two-dimensional (2D) images. The probe connects to a computer that will link to the FACBC PET-CT scan results that the participant has already had performed. These combined images will provide a three-dimensional (3D) image from the FACBC PET-CT scan previously obtained as well as real-time, 2D ultrasound images, resulting in an improved visualization tool to target the biopsy needle to a suspicious lesion.~The needle tip position for each biopsy sample will be recorded on the real-time ultrasound images; this information allows the physician to either re-biopsy the same area for a follow-up examination or not to re-biopsy the same region if the original biopsy was negative.~This biopsy process is estimated to take about 10 minutes.
Study NCT02744534 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard transrectal ultrasound (TRUS) guided biopsy
Description: A lubricated ultrasound probe of about 2.5 cm in diameter is gently inserted into the rectum and a local anesthetic to numb the prostate is administered. The ultrasound probe allows visualization of the prostate in two-dimensional (2D) images and allows for the placement of a biopsy needle that collects samples of the prostate. Usually, a total of 12 biopsy specimens are collected. The procedure takes about 20 minutes. This TRUS-guided biopsy is considered as the standard method for prostate cancer diagnosis.
Study NCT02744534 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard transrectal ultrasound (TRUS) guided biopsy
Description: A lubricated ultrasound probe of about 2.5 cm in diameter is gently inserted into the rectum and a local anesthetic to numb the prostate is administered. The ultrasound probe allows visualization of the prostate in two-dimensional (2D) images and allows for the placement of a biopsy needle that collects samples of the prostate. Usually, a total of 12 biopsy specimens are collected. The procedure takes about 20 minutes. This TRUS-guided biopsy is considered as the standard method for prostate cancer diagnosis.
Study NCT04654780 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Taxes
Description: a High in food tax will be applied to study changes in purchasing and consumption behavior of participants in this group. The tax will correspond to a 20% increase over the market price, that is, a tax that reaches the levels recommended by the WHO.
Study NCT04654780 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Subsidies
Description: A subsidy will be applied to fruits and vegetables that means a reduction of 20% in their price, to study the changes in purchasing behavior and of the participants of said group.
Study NCT04654780 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Average or current food prices will apply. Based on the average of the values reported by three supermarkets
Study NCT03939052 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Free amino acids intake
Description: Oral consumption of eight hourly experimental meals- -4 tracer free experimental meals containing a mixture of free amino acids and calories from protein free flavoured liquid, protein free cookies and corn oil -4 isotopically labeled experimental meals. The same protocol will be repeated with glycomacropeptide (GMP).
Study NCT04326543 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Swanson, Noolan and Phelham - IV edition (SNAP-IV); Conners' Parent Rating Scales (CPRS)
Description: * Ratings on the Swanson, Nolan and Pelham Evaluation Scale - IV (Bussing et al., 2008), were assessed during baseline visit for participants at the time of research assessment, to exclude the presence of ADHD symptoms in the healthy subjects. This scale is composed of 26 items for ADHD symptoms and ODD and was administered at baseline and at follow-up visit.~* Temperament assessment: we used the Mary Rothbart's Temperament Questionnaire, a caregivers' report measure designed to provide a detailed assessment of temperament.~* ADHD Rating scales: the Long Version of Conners' Parent Rating Scale (Conners et al., 1998) was used to quantify ADHD comorbidity symptoms, as ODD and Anxiety traits, in the children and adolescents with ADHD.~* Salivary cortisol: Sampling was performed during one ordinary weekday between 7 and 8 o'clock, within 60' after nocturnal awakening.
Study NCT02035202 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone
Description: A smartphone platform will be used to deliver the CBT2go behavioral intervention and the surveys in the EMA-only arm.
Study NCT02035202 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone
Description: A smartphone platform will be used to deliver the CBT2go behavioral intervention and the surveys in the EMA-only arm.
Study NCT00894439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI-489/Piperacillin
Study NCT00894439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI-489
Study NCT00894439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin
Study NCT00893412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fast-release Orodispersible Tramadol Tablet (Tradonal odis®)
Description: 1 tablet of 50 mg Fast-release Orodispersible Tramadol Tablet (Tradonal odis®)
Study NCT00893412 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Hysterosalpingography (HSG)
Description: One HSG using a metal canula or balloon catheter, 30 minutes after tablet
Study NCT00893412 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hysterosalpingography (HSG)
Description: One HSG using a metal canula or balloon catheter, 30 minutes after tablet
Study NCT00893412 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01055691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin/Metformin
Description: Fixed dose combination dapagliflozin/metformin IR tablet 2.5 mg/850 mg Oral Single dose
Study NCT01055691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: dapagliflozin tablet 2.5 mg Oral Single dose
Study NCT01055691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: metformin IR tablet 850 mg Oral Single dose
Study NCT01055691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin/Metformin
Description: Fixed dose combination dapagliflozin/metformin IR tablet 5 mg/1000 mg Oral Single dose
Study NCT01055691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: dapagliflozin tablet 5 mg Oral Single dose
Study NCT01055691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: metformin IR tablet 1000 mg Oral Single dose
Study NCT02693145 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anti-Retroviral Treatment and Access to Services (ARTAS)
Description: Anti-Retroviral Treatment and Access to Services (ARTAS) is an individual-level, multi-session, time-limited intervention with the goal of linking recently diagnosed persons with HIV to medical care soon after receiving their positive test result. ARTAS is based on the Strengths-based Case Management (SBCM) model, which is rooted in Social Cognitive Theory (particularly self-efficacy) and Humanistic Psychology. SBCM is a model that encourages the client to identify and use personal strengths; create goals for himself/herself; and establish an effective, working relationship with the Linkage Coordinator (LC).
Study NCT03992027 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CF-CBT: A Cognitive-Behavioral Skills-Based Program to Promote Emotional Well-Being for Adults wtih Cystic Fibrosis
Description: CF-CBT is an 8-session program introducing cognitive-behavioral coping skills for managing stress, and for prevention and treatment of anxiety and depression. The content of the program was developed to address stressors related to coping with cystic fibrosis. Participants will receive a patient workbook, and meet with a trained member of the CF team (interventionist) who will guide them through learning and practicing coping skills during 8 weekly sessions.